Citations

Clear

5 citation(s) found for "Shah, Muhammad".

Exploring the landscape of viral hepatitis: A comprehensive retrospective analysis of mortality trends and disparities in the United States (1999–2020)
Idrees, Usama , Nasir, Safa , Marsool, Mohammad Dheyaa, Saeed, Humza, Fatima, Zainab , Mujeeb, Aafeen , Saeed, Khansha, Shahid, Iqra , Sehar, Ayesha, Imtiaz, Abdullah, Alam, Md Shah , Ahmad, Muhammad Husnain , Marsool, Mohammad Dheyaa Marsool, Saeed, Humza , Saeed, Khansha, Najafi, Syed Muhammad Ali, Ahmed, Ali

Mayo Clinic

Medicine | November 14, 2025 | Volume: 104 | Issue: 46 | Pages: e45793

10.1097/md.0000000000045793 | PMID 41239636 Get It

Viral hepatitis (VH) remains a leading cause of preventable mortality in the United States (US). Despite advancements in antiviral therapies, disparities in VH-related mortality persist across demographic, racial, and geographic groups. This study analyzes trends in VH-related mortality among US adults between 1999 and 2020 to identify high-risk subgroups and inform public health interventions. This retrospective cohort study analyzed VH-related deaths among US adults (≥25 years). Data were obtained from the CDC WONDER database, with cases identified using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes B15–B19. Age-adjusted mortality rates (AAMRs) were calculated per 1,00,000 individuals and stratified by age, gender, race and geographical location. Temporal trends in mortality were analyzed by estimating annual percentage changes (APCs) in the AAMRs using the joinpoint regression model. A total of 3,59,035 VH-related deaths were recorded among US adults during 1999 to 2020 with a cumulative overall AAMR of 7.36 (95% CI: 7.33–7.38). Overall, the AAMRs increased significantly from 1999 to 2013 (APC: +3.21; P < .01), followed by a significant decline until 2020 (APC: −5.61; P < .01). Men exhibited higher AAMRs than women, with middle-aged adults (45–64 years) most affected compared to young (25–44 years) and older adults (65 to 85+ years). Non-Hispanic (NH) American Indians/Alaska experienced the highest AAMRs followed by NH Blacks/African Americans, Hispanics, NH Asians/Pacific Islanders and NH Whites populations. Geographically, mortality rates were higher in urban areas than in rural areas, in the Western region relative to other regions and in the District of Columbia compared to other states. Significant disparities in VH-related mortality persist across demographic and geographic subgroups, with particularly higher rates among men, NH American Indian/Alaska Native population, middle-aged adults, and residents of urban and Western US regions. Targeted public health strategies are essential to address these inequities and improve outcomes.
Clinical and imaging presentations are associated with function in incidental adrenocortical adenomas: a retrospective cohort study
Hamidi, Oksana , Shah, Muhammad Shahmeer Ullah , Zhang, Catherine D , Lazik, Natalia, Li, Dingfeng , Singh, Sumitabh , Iñiguez‐Ariza, Nicole M. , Raman, Ram, Carafone, Lindsay , Khanna, Aakanksha, Yan, Qi , Natt, Neena, Hartman, Robert P. , McKenzie, Travis J. , Yan, Qi , Bancos, Irina , Hamidi, Oksana , Shah, Muhammad, Hurtado, Maria D. , Young, William F. , Bancos, Irina

Mayo Clinic

European Journal of Endocrinology | June 28, 2024 | Volume: 191 | Issue: 1 | Pages: 47-54

10.1093/ejendo/lvae078 | PMID 38941271 Get It

Abstract Objective The aim of this study is to assess whether clinical and imaging characteristics are associated with the hormonal subtype, growth, and adrenalectomy for incidental adrenal cortical adenomas (ACAs). Design This is a single-center cohort study. Methods Consecutive adult patients with incidental ACA were diagnosed between 2000 and 2016. Results Of the 1516 patients with incidental ACA (median age 59 years, 62% women), 699 (46%) had nonfunctioning adenomas (NFAs), 482 (31%) had mild autonomous cortisol secretion (MACS), 62 (4%) had primary aldosteronism (PA), 39 (3%) had Cushing syndrome, 18 (1%) had PA and MACS, and 226 (15%) had incomplete work-up. Age, sex, tumor size, and tumor laterality, but not unenhanced computed tomography Hounsfield units (HU), were associated with hormonal subtypes. In a multivariable analysis, ≥1 cm growth was associated with younger age (odds ratio [OR] = 0.8 per 5-year increase, P = .0047) and longer imaging follow-up (OR = 1.2 per year, P &lt; .0001). Adrenalectomy was performed in 355 (23%) patients, including 38% of MACS and 15% of NFA. Adrenalectomy for NFA and MACS was more common in younger patients (OR = 0.79 per 5-year increase, P = .002), larger initial tumor size (OR = 2.3 per 1 cm increase, P &lt; .0001), ≥1 cm growth (OR = 15.3, P &lt; .0001), and higher postdexamethasone cortisol (OR = 6.6 for &gt;5 vs &lt;1.8 μg/dL, P = .002). Conclusions Age, sex, tumor size, and laterality were associated with ACA hormonal subtype and can guide diagnosis and management. Tumor growth was more common with younger age and longer follow-up. Unenhanced HU did not predict hormonal subtype or growth. Adrenalectomy for MACS and NFA was mainly performed in younger patients with larger tumor size, growth, and elevated postdexamethasone cortisol.
Toxicities of CAR T-cell therapy: a review of current literature
Shah, Syed Muhammad Ismail , Rani, Anooja , Kazmi, Sana , Savul, Ilma Saleh , Ukrani, Janta, Khan, Farmanullah , Hasan, Chaudhary A., Rathore, Navin, Syed, Maria , Keswani, Shiwani, Surkasha, FNU, Mal, Doongro, Kumar, Dileep , Asghar, Muhammad Sohaib

Mayo Clinic

Annals of Medicine & Surgery | October 20, 2023 | Volume: 85 | Issue: 12 | Pages: 6013-6020

10.1097/ms9.0000000000001375 | PMID 38098580 Get It

The chimeric antigen receptor (CAR) design, first invented by Zelig Eshhar, paved the way for the use of genetically modified T-cells in targeted therapy against cancer cells. Since then, it has gone through many generations, especially with the integration of co-stimulation in the second and third-generation CARs. However, it also mounts a hyperactive immune response named as cytokine release syndrome with the release of several cytokines eventually resulting in multiple end-organ toxicities. The severity of cytokine release syndrome depends upon certain factors such as the tumor burden, choice of co-stimulation, and degree of lymphodepletion, and can manifest as pulmonary edema, vascular leak, renal dysfunction, cardiac problems, hepatic failure, and coagulopathy. Many grading criteria have been used to define these clinical manifestations but they lack harmonization. Neurotoxicity has also been significantly associated with CAR T-cell therapy but it has not been studied much in previous literature. This review aims to provide a comprehensive account of the clinical manifestations, diagnosis, management, and treatment of CAR T-cell associated neurotoxicity.
S990 Analysis of Changes in the Incidence, Prevalence, Mortality, and Disability-Adjusted Life Years of Inflammatory Bowel Disease in the United States Between 2000-2019 Using the Global Burden of Diseases Database
Jaber, Fouad , Mohamed, Wael T. , Miran, Muhammad Shah, Ghoz, Hassan , Alsakarneh, Saqr , Abboud, Yazan , Ahmed, Mohamed Sabry , Hashash, Jana G. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S748-S750

10.14309/01.ajg.0000953600.90207.c7 Get It

DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis
Tamhane, Shrikant , Shah, Muhammad Shahmeer Ullah , Delivanis, Danae A. , Alahdab, Fares , Arlt, Wiebke , Murad, M. Hassan , Shah, Muhammad, Bancos, Irina , Faßnacht, Martin , Murad, M Hassan , Arlt, Wiebke , Alahdab, Fares

Mayo Clinic

European Journal of Endocrinology | June 2, 2016 | Volume: 175 | Issue: 2 | Pages: R65-R80

10.1530/eje-16-0297 | PMID 27257146 Get It

Objective To perform a systematic review of published literature on adrenal biopsy and to assess its performance in diagnosing adrenal malignancy. Methods Medline In-Process and Other Non-Indexed Citations, MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trial were searched from inception to February 2016. Reviewers extracted data and assessed methodological quality in duplicate. Results We included 32 observational studies reporting on 2174 patients (39.4% women, mean age 59.8 years) undergoing 2190 adrenal mass biopsy procedures. Pathology was described in 1621/2190 adrenal lesions (689 metastases, 68 adrenocortical carcinomas, 64 other malignancies, 464 adenomas, 226 other benign, 36 pheochromocytomas, and 74 others). The pooled non-diagnostic rate (30 studies, 2013 adrenal biopsies) was 8.7% (95%CI: 6–11%). The pooled complication rate (25 studies, 1339 biopsies) was 2.5% (95%CI: 1.5–3.4%). Studies were at a moderate risk for bias. Most limitations related to patient selection, assessment of outcome, and adequacy of follow-up. Only eight studies (240 patients) could be included in the diagnostic performance analysis with a sensitivity and specificity of 87 and 100% for malignancy, 70 and 98% for adrenocortical carcinoma, and 87 and 96% for metastasis respectively. Conclusions Evidence based on small sample size and moderate risk of bias suggests that adrenal biopsy appears to be most useful in the diagnosis of adrenal metastasis in patients with a history of extra-adrenal malignancy. Adrenal biopsy should only be performed if the expected findings are likely to alter the management of the individual patient and after biochemical exclusion of catecholamine-producing tumors to help prevent potentially life-threatening complications.